<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://rheumatology.oxfordjournals.org">
<title>Rheumatology - current issue</title>
<link>http://rheumatology.oxfordjournals.org</link>
<description>Rheumatology - RSS feed of current issue</description>
<prism:eIssn>1462-0332</prism:eIssn>
<prism:coverDisplayDate>August 2008</prism:coverDisplayDate>
<prism:publicationName>Rheumatology</prism:publicationName>
<prism:issn>1462-0324</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1111?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1114?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1117?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1124?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1132?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1137?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1144?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1151?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1156?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1160?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1168?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1172?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1179?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1185?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1193?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1199?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1203?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1208?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1213?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1219?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1223?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1228?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1231?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1235?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1239?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1244?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1250?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1251?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1252?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1254?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1255?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1256?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1257?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1259?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1259-a?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1260?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1260-a?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261-a?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261-b?rss=1" />
  <rdf:li rdf:resource="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1262?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1111?rss=1">
<title><![CDATA[Germinal centre-like structures in Wegener's granuloma: the morphological basis for autoimmunity?]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1111?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Mueller, A., Holl-Ulrich, K., Lamprecht, P., Gross, W. L.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken202</dc:identifier>
<dc:title><![CDATA[Germinal centre-like structures in Wegener's granuloma: the morphological basis for autoimmunity?]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1113</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1111</prism:startingPage>
<prism:section>EDITORIALS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1114?rss=1">
<title><![CDATA[A potential role for synovial fluid mesenchymal stem cells in ligament regeneration]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1114?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[McGonagle, D., Jones, E.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Osteoarthritis and Cartilage, Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken236</dc:identifier>
<dc:title><![CDATA[A potential role for synovial fluid mesenchymal stem cells in ligament regeneration]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1116</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1114</prism:startingPage>
<prism:section>EDITORIALS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1117?rss=1">
<title><![CDATA[Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1117?rss=1</link>
<description><![CDATA[
<p>The aim of this study was to review the evidence supporting the use of anti-depressants in painful rheumatological conditions. A systematic review of papers published between 1966 and 2007, in five European languages, on anti-depressants in rheumatological conditions was performed. Papers were scored using Jadad method and analgesic ES was calculated. We selected 78 clinical studies and 12 meta-analyses, from 140 papers. The strongest evidence of an analgesic effect of anti-depressants has been obtained for fibromyalgia. A weak analgesic effect is observed for chronic low back pain, with an efficacy level close to that of analgesics. In RA and AS, there is no analgesic effect of anti-depressants, but these drugs may help to manage fatigue and sleep disorders. There is no clear evidence of an analgesic effect inOA, but studies have poor methodological quality. Analgesic effects of anti-depressants are independent of their anti-depressant effects. Tricyclic anti-depressants (TCAs), even at low doses, have analgesic effects equivalent to those of serotonin and noradrenalin reuptake inhibitors (SNRIs), but are less well tolerated. Selective serotonin reuptake inhibitors (SSRIs) have modest analgesic effects, but higher doses are required to achieve analgesia. Anti-depressant drugs, particularly TCAs and SNRIs, have analgesic effects in chronic rheumatic painful states in which analgesics and NSAIDs are not very efficient, such as fibromyalgia and chronic low back pain. In inflammatory rheumatic diseases, anti-depressants may be useful for managing fatigue and sleep disorders. Further studies are required to compare anti-depressants with other analgesics in the management of chronic painful rheumatological conditions.</p>
]]></description>
<dc:creator><![CDATA[Perrot, S., Javier, R.-M., Marty, M., Le Jeunne, C., Laroche, F., the CEDR (Cercle d'Etude de la Douleur en Rhumatologie France), French Rheumatological Society, Pain Study Section]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Pharmacology]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken110</dc:identifier>
<dc:title><![CDATA[Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1123</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1117</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1124?rss=1">
<title><![CDATA[Rheumatoid cachexia: a clinical perspective]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1124?rss=1</link>
<description><![CDATA[
<p>Rheumatoid cachexia is under-recognized in clinical practice. The loss of lean body tissue, which characterizes cachexia, is often compensated for by gain in body fat&mdash;so called &lsquo;cachectic obesity&rsquo;&mdash;so that 85% or more RA patients have a normal BMI. Severe cachexia with loss of weight leads to increased morbidity and premature mortality but loss of muscle bulk with a normal BMI also associates with poor clinical outcomes. Increasing BMI, even into the obese range, is associated with less joint damage and reduced mortality. Measurement of body composition using DXA and other techniques is feasible but the results must be interpreted with care. Newer techniques such as whole-body MRI will help define with more confidence the mass and distribution of fat and muscle and help elucidate the relationships between body composition and outcomes. Cachexia shows little response to diet alone but progressive resistance training and anti-TNF therapies show promise in tackling this potentially disabling extra-articular feature of RA.</p>
]]></description>
<dc:creator><![CDATA[Summers, G. D., Deighton, C. M., Rennie, M. J., Booth, A. H.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken146</dc:identifier>
<dc:title><![CDATA[Rheumatoid cachexia: a clinical perspective]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1131</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1124</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1132?rss=1">
<title><![CDATA[Demystifying acupuncture]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1132?rss=1</link>
<description><![CDATA[
<p>Acupuncture refers to the insertion of fine needles into the body at specific points for a therapeutic effect. The term comes from the Latin words &lsquo;acus&rsquo; (needle) and &lsquo;punctura&rsquo; (to puncture). The technique has been practiced in the Far East for at least 3000 yrs but it is only in the last 30 yrs that interest has developed in the West underpinned by increasing scientific research. One of the main uses of acupuncture has been to treat musculoskeletal pain and this article will review the evidence base and outline the main theories of mechanisms of action.</p>
]]></description>
<dc:creator><![CDATA[Pyne, D., Shenker, N. G.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Psychology: Measurement and Management of Pain]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken161</dc:identifier>
<dc:title><![CDATA[Demystifying acupuncture]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1136</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1132</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1137?rss=1">
<title><![CDATA[Synovial fluid-derived mesenchymal stem cells increase after intra-articular ligament injury in humans]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1137?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> The existence of mesenchymal stem cells (MSCs) in SF was previously reported. However, the behaviour and properties of MSCs derived from SF have not been fully elucidated.</p>
<p><b>Methods.</b> Human SFs were obtained from 19 knee joints with anterior cruciate ligament injury around the time of reconstruction surgery, and from three healthy volunteers. SF was plated, cultured and examined for colony-forming number, <I>in vitro</I> differentiation, surface epitopes and gene profiles. Also, rabbit synovium-MSCs were injected into the knee joint in a rabbit partial anterior cruciate ligament defect model, and the injected cells were traced.</p>
<p><b>Results.</b> SF-MSCs from IA ligament injury patients were 100 times more in number than those from healthy volunteers. Total colony number was positively correlated with post-injury period. No significant differences were observed among the cells derived from SF around the time of the surgery in relation to surface epitopes and differentiation potentials. Cluster analysis of gene profiles demonstrated that SF-MSCs were more similar to synovium MSCs than bone marrow MSCs. In rabbit experiments, the MSCs injected into the knee in which IA ligament was partially defective were observed more on the defected area than on the intact area of the ligament at 24 h.</p>
<p><b>Conclusion.</b> We demonstrated that SF-MSCs, similar to synovium MSCs, increased in number after IA ligament injury and surgery without marked alteration of the properties.</p>
]]></description>
<dc:creator><![CDATA[Morito, T., Muneta, T., Hara, K., Ju, Y.-J., Mochizuki, T., Makino, H., Umezawa, A., Sekiya, I.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Osteoarthritis and Cartilage, Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken114</dc:identifier>
<dc:title><![CDATA[Synovial fluid-derived mesenchymal stem cells increase after intra-articular ligament injury in humans]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1143</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1137</prism:startingPage>
<prism:section>BASIC SCIENCE</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1144?rss=1">
<title><![CDATA[Natural antibodies against phosphorylcholine as potential protective factors in SLE]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1144?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> We have recently reported that natural antibodies against phosphorylcholine (anti-PC) have atheroprotective properties. Here we compare anti-PC with other autoantibodies in SLE patients with and without cardiovascular disease (CVD).</p>
<p><b>Methods.</b> Twenty-six women (52 &plusmn; 8.2 yrs) with SLE and a history of CVD (SLE cases) were compared with 26 age-matched women with SLE without CVD (SLE controls) and 26 age-matched population-based control women (controls). PC was conjugated with BSA (PC-BSA) or keyhole-limpet haemocyanin (PC-KLH). Anti-PC and antibodies against phosphatidylserine (anti-PS) and BSA (anti-BSA) were studied by ELISA. Anti-PC-IgG were extracted from intravenous immunoglobulin (IVIG). Activation of endothelial cells by platelet-activating factor (PAF) was studied with FACScan.</p>
<p><b>Results.</b> IgG anti-PC-BSA and anti-PC-KLH were decreased among SLE-cases and SLE-controls as compared with controls (<I>P</I> &lt; 0.005 and <I>P</I> &lt; 0.05), respectively. SLE cases were more prevalent in the lowest 25th percentile of anti-PC-IgM (and IgG) as compared with controls (<I>P</I> &lt; 0.05) but anti-PC-IgM levels did not differ significantly between groups. Among SLE controls, anti-PC-BSA were associated negatively with organ damage (SLICC) and disease activity (SLEDAI) (<I>P</I> &lt; 0.05). Among SLE cases, anti-PC-BSA and anti-PC-KLH were associated negatively with SLICC (<I>P</I> = 0.021; <I>P</I> = 0.010) and anti-PC-BSA was negatively associated with SLEDAI (<I>P</I> &lt; 0.039).</p>
<p>Anti-PS-IgG and anti-BSA-IgG were raised among SLE cases as compared with other groups (<I>P</I> &lt; 0.05) and did not cross-react with anti-PC. Anti-PC-IgG could be extracted from IVIG and inhibited PAF-induced expression of adhesion molecules.</p>
<p><b>Conclusion.</b> Low levels of anti-PC could be of importance in SLE. Anti-BSA and anti-PS and low levels of anti-PC could contribute to development of CVD in SLE.</p>
]]></description>
<dc:creator><![CDATA[Su, J., Hua, X., Concha, H., Svenungsson, E., Cederholm, A., Frostegard, J.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Systemic Lupus Erythematosus and Autoimmunity]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken120</dc:identifier>
<dc:title><![CDATA[Natural antibodies against phosphorylcholine as potential protective factors in SLE]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1150</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1144</prism:startingPage>
<prism:section>BASIC SCIENCE</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1151?rss=1">
<title><![CDATA[Non-traumatic necrosis of bone (osteonecrosis) is associated with endothelial cell activation but not thrombophilia]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1151?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> The pathophysiology of non-traumatic osteonecrosis (ON) or avascular necrosis (AVN) of the femoral head remains poorly understood. Some studies have suggested the contribution of underlying thrombophilia as a mechanism; however, no specific thrombophilic factor has been consistently found in association with the disease. We are presenting data suggesting a role for endothelial cell activation rather than thrombophilia in ON.</p>
<p><b>Methods.</b> A prospective consecutive cohort of 49 patients with a diagnosis of ON. The disease was considered idiopathic in five and secondary in 44 patients. The investigation included a coagulation and thrombophilia profile, endothelial cell activation and non-specific inflammatory markers as well as a biochemical profile. Statistical analysis using Fisher's exact test was obtained to assess correlation between endothelial cell markers and variables of inflammation.</p>
<p><b>Results.</b> Patients with non-traumatic ON were not found to have a specific underlying thrombophilic factor compared with the general population. Out of 49 patients,19 had elevation of at least one endothelial cell markers. We found that activation of endothelial cell markers was independently correlated to ON but not correlated to the presence of inflammation (<I>P</I> = 1.0000).</p>
<p><b>Conclusion.</b> These results suggest that non-traumatic ON is not associated with a specific thrombophilic abnormality in those affected. This study demonstrates a potential association between regional endothelial dysfunction and ON. More studies are needed at a molecular level to further investigate the specific role of endothelium in the physiopathology of ON. A better understanding of the underlying mechanism could lead to potential preventive and therapeutic strategies of this devastating disease.</p>
]]></description>
<dc:creator><![CDATA[Seguin, C., Kassis, J., Busque, L., Bestawros, A., Theodoropoulos, J., Alonso, M.-L., Harvey, E. J.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Osteoporosis and Metabolic Bone Disease]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken206</dc:identifier>
<dc:title><![CDATA[Non-traumatic necrosis of bone (osteonecrosis) is associated with endothelial cell activation but not thrombophilia]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1155</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1151</prism:startingPage>
<prism:section>BASIC SCIENCE</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1156?rss=1">
<title><![CDATA[Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1156?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> To examine the role of adenosine receptor 2a gene (ADORA2a) polymorphisms on outcome of MTX treatment in RA.</p>
<p><b>Methods.</b> Subjects included 309 RA patients with a defined response to MTX. Patients were included if they were (i) good responders (<I>n</I> = 147) (ESR &lt;20 for &gt;6/12 on stable dose of MTX) (ii) inefficacy failures (<I>n</I> = 101) (physician statement and failure to reduce ESR/CRP by 20%) or (iii) adverse event (AE) failures (<I>n</I> = 61) (verified by medical record review). AEs were sub-divided into gastrointestinal (GI) (<I>n</I> = 24), abnormal LFTs (<I>n</I> = 20) or other (<I>n</I> = 17). 8 single nucleotide polymorphisms (SNPs) within ADORA2a were genotyped using the Sequenom MALDI-TOF platform.</p>
<p><b>Results.</b> Five SNPs within ADORA2a were associated with stopping MTX for AEs (OR 2.1&ndash;3.07, <I>P</I> &lt; 0.05 for all). Analysis by AE type showed that the association was specific for GI toxicity. No association was observed between ADORA2a and inefficacy outcomes.</p>
<p><b>Conclusion.</b> Genetic variation within ADORA2a is significantly associated with AEs on MTX, specifically GI AEs. Knowledge of the ADORA2a genotype may help to improve identification of patients at high risk of GI toxicity with MTX.</p>
]]></description>
<dc:creator><![CDATA[Hider, S. L., Thomson, W., Mack, L. F., Armstrong, D. J., Shadforth, M., Bruce, I. N.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Pharmacology, Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken182</dc:identifier>
<dc:title><![CDATA[Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1159</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1156</prism:startingPage>
<prism:section>BASIC SCIENCE</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1160?rss=1">
<title><![CDATA[Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1160?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> The aetiology of SAPHO (synovitis, acne, palmoplantar pustulosis, hyperostosis, osteitis) syndrome seems to involve genetic, infectious and immunological components. We examined innate and adaptive immune responses in SAPHO syndrome, as compared with PsA and RA. We also studied the effect of etanercept on immunological parameters.</p>
<p><b>Methods.</b> We studied 29 patients with SAPHO syndrome, as well as 22 patients with RA, 21 patients with PsA and 15 healthy controls. Adaptive immune responses were investigated by assaying total serum immunoglobulins and several autoantibodies. Innate immunity was studied by quantifying blood PMN functions and plasma cytokine levels. PMN responses to <I>Propionibacterium acnes</I> were tested <I>ex vivo</I>. Eight patients who received etanercept for refractory rheumatic disorders were tested before and after 28 days of treatment.</p>
<p><b>Results.</b> SAPHO syndrome was associated with elevated IL-8 and IL-18 plasma levels. IL-8 and TNF- production by purified PMN was higher in the three patient groups than in the healthy controls, but the oxidative burst and IL-18 production were normal. No autoantibodies were detected in SAPHO patients. Induction of PMN IL-8 and TNF- production by <I>P. acnes</I> was impaired in the SAPHO group as compared with the RA and PsA groups. After 28 days of etanercept therapy, PMN IL-8 and TNF- production was down-regulated and TNF- plasma levels were increased.</p>
<p><b>Conclusions.</b> These results support the view that the SAPHO syndrome may be triggered by an infectious state involving <I>P. acnes</I>, contributing to the strong humoral and cellular pro-inflammatory responses. Etanercept modulation of PMN activation status emphasizes these new immunological findings.</p>
]]></description>
<dc:creator><![CDATA[Hurtado-Nedelec, M., Chollet-Martin, S., Nicaise-Roland, P., Grootenboer-Mignot, S., Ruimy, R., Meyer, O., Hayem, G.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Spondylarthropathies, Soft Tissue Rheumatism, Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken185</dc:identifier>
<dc:title><![CDATA[Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1167</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1160</prism:startingPage>
<prism:section>BASIC SCIENCE</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1168?rss=1">
<title><![CDATA[Mannose-binding lectin polymorphisms are not associated with rheumatoid arthritis--confirmation in two large cohorts]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1168?rss=1</link>
<description><![CDATA[
<p><b>Objectives.</b> In RA, conflicting results have been described on the association between genotypes of the complement factor mannose-binding lectin (MBL) and disease susceptibility and severity. This might be due to underpowerment of previous research work and the fact that no confirmation cohorts were used. Therefore a different approach is warranted.</p>
<p><b>Methods.</b><I>MBL2</I> gene polymorphisms were determined in two RA cohorts (378 and 261 cases) and 648 controls. Considering MBL polymorphisms, cases and controls were categorized in groups of high, intermediate and low MBL production. The total sample size allows detection of a potential association between RA susceptibility and MBL groups with an odds ratio of 1.37 ( &lt; 0.05; 1&ndash;&beta; &gt; 0.8). Disease severity as defined by the need for anti-TNF therapy was also analysed for possible associations with MBL groups.</p>
<p><b>Results.</b> There was no difference in the frequencies between MBL genotypes of RA cases and controls that are associated with high (cases 54.4%, controls 57.0%), intermediate (cases 28.9%, controls 27.5%) or low (cases 16.7%, controls 15.5%) MBL production. Furthermore, there was no association between MBL groups and disease severity.</p>
<p><b>Conclusions.</b> MBL genotype groups are not associated with RA disease susceptibility or severity in this large study including a confirmation cohort. Compared with previous smaller studies these results add to more definite conclusions.</p>
]]></description>
<dc:creator><![CDATA[van de Geijn, F. E., Hazes, J. M. W., Geleijns, K., Emonts, M., Jacobs, B. C., Dufour-van den Goorbergh, B. C. M., Dolhain, R. J. E. M.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken226</dc:identifier>
<dc:title><![CDATA[Mannose-binding lectin polymorphisms are not associated with rheumatoid arthritis--confirmation in two large cohorts]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1171</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1168</prism:startingPage>
<prism:section>BASIC SCIENCE</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1172?rss=1">
<title><![CDATA[Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1172?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> IA therapy with hyaluronan (HA) is reported to provide symptomatic relief and disease modification in OA. This study assessed the pathological changes in the synovium of an ovine model of OA and evaluated the effects of two HA preparations on this pathology.</p>
<p><b>Methods.</b> Eighteen sheep had bilateral lateral meniscectomy to induce OA. Four months post-surgery animals received IA saline or HA (Hyalgan&reg;) weekly for 5 weeks or three injections of an amide derivative of HA (HYADD&reg;4-G) every 2 weeks (<I>n</I> = 6 per group). Six months after meniscectomy, sheep were killed, knee joint synovium processed, scored for pathological change and compared with synovium from non-operated animals. Sections of synovium from normal and treated joints were also immunostained for TNF-, HSP-47, TGF-&beta;, CD44, connective tissue growth factor (CTGF) or iNOS. HA synthesis by synovial fibroblasts isolated from each OA joint was quantified.</p>
<p><b>Results.</b> Aggregate scores of pathological change were higher in OA joint synovia compared with controls, with individual measures of subintimal fibrosis and vascularity predominantly affected. Depth of intimal fibrosis was also significantly higher in meniscectomized joints. IA treatment with Hyalgan&reg; decreased aggregate score, vascularity and depth of fibrosis. HYADD&reg;4-G treatment decreased vascularity, intimal hyperplasia and increased high-molecular weight HA synthesis by synovial fibroblasts. CD44, CTGF or iNOS expression was increased in the synovial lining of OA joints compared with normal, but there was no significant modulation of this increase by either HA preparation.</p>
<p><b>Conclusion.</b> Increased fibrosis and vascularity are hallmarks of pathological change in synovium in this meniscectomy model of OA. Both the IA HA and an amide derivative of HA reduced aspects of this pathology thus providing a potential mechanism for improving joint mobility and function in OA.</p>
]]></description>
<dc:creator><![CDATA[Smith, M. M., Cake, M. A., Ghosh, P., Schiavinato, A., Read, R. A., Little, C. B.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Osteoarthritis and Cartilage, Experimental Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken219</dc:identifier>
<dc:title><![CDATA[Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1178</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1172</prism:startingPage>
<prism:section>BASIC SCIENCE</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1179?rss=1">
<title><![CDATA[Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1179?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> GCA carries an increased risk of developing thoracic aortic aneurysms. Previous work with fluorodeoxyglucose (FDG)-PET has shown that the aorta is frequently involved in this type of vasculitis. We wanted to investigate whether there is a correlation between the extent of vascular FDG uptake during the acute phase of GCA and the aortic diameter at late follow-up.</p>
<p><b>Methods.</b> All patients with biopsy-proven GCA who ever underwent an FDG-PET scan in our centre were asked to undergo a CT scan of the aorta. The diameter of the aorta was measured at six different levels (ascending aorta, aortic arch, descending aorta, abdominal suprarenal, juxtarenal and infrarenal aorta) and the volumes of the thoracic and of the abdominal aorta were calculated.</p>
<p><b>Results.</b> Forty-six patients agreed to participate (32 females, 14 males). A mean of 46.7 &plusmn; 29.9 months elapsed between diagnosis and CT scan. All aortic dimensions were significantly smaller in women than in men, except for the diameter of the ascending aorta. Patients who had an increased FDG uptake in the aorta at diagnosis of GCA, had a significantly larger diameter of the ascending aorta (<I>P</I> = 0.025) and descending aorta (<I>P</I> = 0.044) and a significantly larger volume of the thoracic aorta (<I>P</I> = 0.029). In multivariate analysis, FDG uptake at the thoracic aorta was associated with late volume of the thoracic aorta (<I>P</I> = 0.039).</p>
<p><b>Conclusion.</b> GCA-patients with increased FDG uptake in the aorta may be more prone to develop thoracic aortic dilatation than GCA patients without this sign of aortic involvement.</p>
]]></description>
<dc:creator><![CDATA[Blockmans, D., Coudyzer, W., Vanderschueren, S., Stroobants, S., Loeckx, D., Heye, S., De Ceuninck, L., Marchal, G., Bobbaers, H.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken119</dc:identifier>
<dc:title><![CDATA[Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1184</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1179</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1185?rss=1">
<title><![CDATA[The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1185?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> Systemic sclerosis (SSc) is a rare, heterogeneous disease, which affects different organs and therefore requires interdisciplinary diagnostic and therapeutic management. To improve the detection and follow-up of patients presenting with different disease manifestations, an interdisciplinary registry was founded with contributions from different subspecialties involved in the care of patients with SSc.</p>
<p><b>Methods.</b> A questionnaire was developed to collect a core set of clinical data to determine the current disease status. Patients were grouped into five descriptive disease subsets, i.e. lcSSc, dcSSc, SSc sine scleroderma, overlap-syndrome and UCTD with scleroderma features.</p>
<p><b>Results.</b> Of the 1483 patients, 45.5% of patients had lcSSc and 32.7% dcSSc. Overlap syndrome was diagnosed in 10.9% of patients, while 8.8% had an undifferentiated form. SSc sine scleroderma was present in 1.5% of patients. Organ involvement was markedly different between subsets; pulmonary fibrosis for instance was significantly more frequent in dcSSc (56.1%) than in overlap syndrome (30.6%) or lcSSc (20.8%). Pulmonary hypertension was more common in dcSSc (18.5%) compared with lcSSc (14.9%), overlap syndrome (8.2%) and undifferentiated disease (4.1%). Musculoskeletal involvement was typical for overlap syndromes (67.6%). A family history of rheumatic disease was reported in 17.2% of patients and was associated with early disease onset (<I>P</I> &lt; 0.005).</p>
<p><b>Conclusion.</b> In this nationwide register, a descriptive classification of patients with disease manifestations characteristic of SSc in five groups allows to include a broader spectrum of patients with features of SSc.</p>
]]></description>
<dc:creator><![CDATA[Hunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., Moinzadeh, P., Muller-Ladner, U., Pfeiffer, C., Riemekasten, G., Schulze-Lohoff, E., Sunderkoetter, C., Weber, M., Worm, M., Klaus, P., Rubbert, A., Steinbrink, K., Grundt, B., Hein, R., Scharffetter-Kochanek, K., Hinrichs, R., Walker, K., Szeimies, R.-M., Karrer, S., Muller, A., Seitz, C., Schmidt, E., Lehmann, P., Foeldvari, I., Reichenberger, F., Gross, W.L., Kuhn, A., Haust, M., Reich, K., Bohm, M., Saar, P., Fierlbeck, G., Kotter, I., Lorenz, H.-M., Blank, N., Grafenstein, K., Juche, A., Aberer, E., Bali, G., Fiehn, C., Stadler, R., Bartels, V.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Systemic Sclerosis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken179</dc:identifier>
<dc:title><![CDATA[The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1192</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1185</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1193?rss=1">
<title><![CDATA[The Sjogren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1193?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> To validate a tool for assessment of accumulated damage in patients with Primary SS (PSS).</p>
<p><b>Methods.</b> Of the total 114 patients fulfilling American&ndash;European Consensus Group (AECG) criteria for PSS 104 were included in the study and assessed by rheumatologists at <I>T</I> (time) = 0 months and <I>T</I> = 12 months. On each occasion, damage and activity data, and autoantibody status were collected. SF-36 and Profile of Fatigue and Discomfort-Sicca Symptoms Inventory (PROFAD-SSI) questionnaires were completed. Cross-sectional analysis of this data was subject to a process of expert validation by 11 ophthalmologists, 14 oral medicine specialists and 8 rheumatologists. Items were removed from the index if &ge; 50% of respondents recommended exclusion. Statistical validation was performed on remaining items. Spearman's rank analysis was used to investigate associations between damage scores and other disease status measures and Wilcoxon matched-pair analysis to assess sensitivity to change in the damage score.</p>
<p><b>Results.</b> Based on the expert validation, a 29-item damage score was agreed incorporating ocular, oral and systemic domains. Total damage score correlated with disease duration at study entry (<I>r</I> = 0.436; <I>P</I> &lt; 0.001), physical function as measured by SF-36 (<I>r</I> = 0.250, <I>T</I> = 0 months; <I>r</I> = 0.261 <I>T</I> = 12 months) and activity as measured by the Sj&ouml;gren's Systemic Clinical Activity Index (<I>r</I> = 0.213, <I>T</I> = 0 months; <I>r</I> = 0.215, <I>T</I> =12 months). Ocular damage score correlated with the &lsquo;eye dry&rsquo; domain of PROFAD-SSI (<I>r</I> = 0.228, <I>T</I> = 0 months; <I>r</I> = 0.365, <I>T</I> = 12 months). Other associations not present on both assessments were considered clinically insignificant. On Wilcoxon analysis, the index was sensitive to change over 12 months (<I>z</I> = &ndash;3.262; <I>P</I> &lt; 0.01).</p>
<p><b>Conclusion.</b> This study begins validation of a tool for collection of longitudinal damage data in PSS. We recommend further trial in both the experimental and clinical environment.</p>
]]></description>
<dc:creator><![CDATA[Barry, R. J., Sutcliffe, N., Isenberg, D. A., Price, E., Goldblatt, F., Adler, M., Canavan, A., Hamburger, J., Richards, A., Regan, M., Gadsby, K., Rigby, S., Jones, A., Mathew, R., Mulherin, D., Stevenson, A., Nightingale, P., Rauz, S., Bowman, S. J.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Sjogren's Syndrome]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken164</dc:identifier>
<dc:title><![CDATA[The Sjogren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1198</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1193</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1199?rss=1">
<title><![CDATA[Concordant and discordant associations between rheumatoid arthritis, systemic lupus erythematosus and ankylosing spondylitis based on all hospitalizations in Sweden between 1973 and 2004]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1199?rss=1</link>
<description><![CDATA[
<p><b>Objectives.</b> To quantify the sibling risk of RA, SLE and AS. To analyse the concordant and discordant associations between RA, SLE and AS.</p>
<p><b>Methods.</b> Follow-up study of all individuals and their siblings born in or after 1932 and hospitalized for RA, SLE or AS between 1973 and 2004 (32 yrs). Data were retrieved from a comprehensive dataconstructed by using several national Swedish data registers, including the Total Population Register, the Swedish Hospital Discharge Register and the Multigeneration Register. Standardized incidence ratios (SIRs) were used to estimate sibling risks.</p>
<p><b>Results.</b> For males, the overall significant SIRs were 4.72, 4.35 and 4.14 for RA, SLE and AS, respectively, if a sibling was affected by any inflammatory disease. The corresponding significant SIRs for females were 4.12, 3.73 and 4.73. The concordant significant SIRs in siblings were 5.12, 17.02 and 17.14 for RA, SLE and AS, respectively. There were also discordant associations between RA and SLE, whereas AS was only associated with AS.</p>
<p><b>Conclusions.</b> This study was able objectively to quantify the sibling risk of RA, SLE and AS, which represents useful knowledge for clinicians and geneticists. The analysis of concordant and discordant associations may be useful in future studies aimed at finding specific genes associated with these diseases.</p>
]]></description>
<dc:creator><![CDATA[Sundquist, K., Martineus, J. C., Li, X., Hemminki, K., Sundquist, J.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Spondylarthropathies, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Autoimmunity]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken184</dc:identifier>
<dc:title><![CDATA[Concordant and discordant associations between rheumatoid arthritis, systemic lupus erythematosus and ankylosing spondylitis based on all hospitalizations in Sweden between 1973 and 2004]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1202</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1199</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1203?rss=1">
<title><![CDATA[Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1203?rss=1</link>
<description><![CDATA[
<p><b>Objectives.</b> Increased incidence of cardiovascular disease (CVD) has been observed in AS. The reasons of this increase are not fully understood (greater prevalence of traditional cardiovascular risks, consequences of treatment (NSAID) or biological inflammation). The objectives of this study are to assess intima&ndash;media thickness (IMT) and arterial stiffness (i.e augmentation index AIx), markers of sub-clinical atherosclerosis in AS patients and to examine the effects of TNF- inhibitors on arterial stiffness in active AS patients.</p>
<p><b>Methods.</b> Sixty AS patients were enrolled with 60 healthy controls. Their BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) scores, ESR and CRP levels were recorded. Subclinical atherosclerosis was assessed by measurement of AIx by pulse wave analysis and IMT by carotid echography.</p>
<p><b>Results.</b> We found significantly increased IMT in the AS group compared with healthy controls. After adjustment for confounding factors, an underlying trend towards increased IMT was still present (<I>P</I> = 0.06). No difference was found in arterial stiffness between the two groups. AS patients, treated or not with anti-TNF- at baseline, had significantly increased IMT and AIx or a trend towards increase. IMT was positively correlated with tobacco use, WHR and blood pressure but not correlated with CRP level. Despite improvement in markers of disease activity, arterial stiffness was unchanged after 14 weeks of treatment with TNF antagonists.</p>
<p><b>Conclusion.</b> This study shows a trend towards increased subclinical atherosclerosis in AS patients. TNF- blockade does not seem to improve arterial stiffness in AS patients, but our results lack statistical power.</p>
]]></description>
<dc:creator><![CDATA[Mathieu, S., Joly, H., Baron, G., Tournadre, A., Dubost, J.-J., Ristori, J.-M., Lusson, J.-R., Soubrier, M.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Spondylarthropathies]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken198</dc:identifier>
<dc:title><![CDATA[Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1207</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1203</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1208?rss=1">
<title><![CDATA[Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1208?rss=1</link>
<description><![CDATA[
<p><b>Objectives.</b> To evaluate the predictive value of <I>TNFRII 196R, PTPN22 1858T</I> and <I>HLA</I>-shared epitope (SE) alleles, RFs and anti-citrullinated protein antibodies (ACPAs) for RA diagnosis in a cohort of patients with very early arthritis.</p>
<p><b>Methods.</b> We followed up 284 patients who had swelling of at least two joints that had persisted for longer than 4 weeks but had been evolving for &lt;6 months. At 2 yrs, patients were classified as having RA or non-RA rheumatic diseases according to the ACR criteria. Patients were genotyped with respect to <I>TNFRII 196M/R</I> and <I>PTPN22 1858C/T</I> polymorphisms and <I>HLA</I>-SE. The presence of IgA, IgG and IgM RF isotypes and ACPA was sought in sera collected at disease onset.</p>
<p><b>Results.</b> <I>HLA</I>-SE alleles alone, concomitant presence of <I>TNFRII 196R</I> and <I>PTPN22 1858T</I> alleles, IgA, IgG and IgM RF alone and ACPA were found to be significantly associated with RA diagnosis. Using logistic regression analysis, the concomitant presence of RF and ACPA at disease onset was the best association to predict RA diagnosis. In patients (<I>n</I> = 34) who did not fulfil the ACR criteria for RA at inclusion but who progressed to ACR positivity, the study of the genetic risk markers did not contribute to predict RA diagnosis at 2 yrs.</p>
<p><b>Conclusions.</b> <I>PTPN22 1858T</I>, <I>TNFRII 196R</I> and <I>HLA</I>-SE alleles do not improve the predictive value of RF and ACPA for RA diagnosis in our cohort, and do not contribute to an earlier diagnosis in undifferentiated patients initially negative for RF and ACPA.</p>
]]></description>
<dc:creator><![CDATA[Goeb, V., Dieude, P., Daveau, R., Thomas-L'Otellier, M., Jouen, F., Hau, F., Boumier, P., Tron, F., Gilbert, D., Fardellone, P., Cornelis, F., Le Loet, X., Vittecoq, O.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken192</dc:identifier>
<dc:title><![CDATA[Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1212</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1208</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1213?rss=1">
<title><![CDATA[Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1213?rss=1</link>
<description><![CDATA[
<p><b>Objectives.</b> Many AS patients report periods of perceived higher disease activity (flares). This pilot study aims to document disease activity patterns reported by AS patients and examine associations with disease-specific health status measures.</p>
<p><b>Methods.</b> Consecutive AS patients (<I>n</I> = 114) were asked whether they experience flares, and if they experience symptoms of AS between flares. They were shown the Flare Illustration of disease patterns over time and asked to select the pattern that best described their disease (i) since symptom onset and (ii) in the past year. Associations between reported disease pattern and disease activity (Bath AS Disease Activity Index, BASDAI); functional impairment (Bath AS Functional Index, BASFI); AS Quality of Life (ASQoL); Back Pain (Nocturnal and Overall) and demographic features were assessed in a subsample (<I>n</I> = 83) (statistical significance defined at <I>P</I> &le; 0.05).</p>
<p><b>Results.</b> Since disease onset 108/113 patients (96%) reported flares, and 82/99 (83%) reported symptoms of AS between flares. Flares typically lasted days or weeks. When patients were asked to characterize their disease pattern using the Flare Illustration, patterns with constant symptoms predominated (&gt;70% of patients) and patterns with constant symptoms since onset (<I>vs</I> intermittent symptoms) were associated with worse health status (ASQoL: <I>P</I> = 0.007; BASDAI: <I>P</I> = 0.029; BASFI: <I>P</I> = 0.013, overall back pain: <I>P</I> = 0.025).</p>
<p><b>Conclusions.</b> Almost all AS patients report flares in disease activity: 70&ndash;80% report constant symptoms with single/repeated flares, while 20&ndash;30% report flares with no intermittent symptoms. The former is associated with a significantly poorer health status. These findings will be validated in a prospective study.</p>
]]></description>
<dc:creator><![CDATA[Stone, M. A., Pomeroy, E., Keat, A., Sengupta, R., Hickey, S., Dieppe, P., Gooberman-Hill, R., Mogg, R., Richardson, J., Inman, R. D.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Spondylarthropathies]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken176</dc:identifier>
<dc:title><![CDATA[Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1218</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1213</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1219?rss=1">
<title><![CDATA[Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1219?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> There is a lack of knowledge on factors that reliably can predict radiological changes in patients with AS. We have investigated whether urinary C-terminal cross-linking telopeptide of type I (CTX-I) and type II (CTX-II) collagen, as specific biochemical markers of bone and cartilage degradation, respectively, are associated with radiological damage and progression, and with BMD in patients with AS.</p>
<p><b>Methods.</b> Eighty-three patients with AS [mean (<scp>s.d</scp>.) age: 50.4 (12) yrs, 65% male, mean (<scp>s.d</scp>.) disease duration after diagnosis: 16.7 (10) yrs] who participate in an ongoing cohort study of patients with AS [Outcome in AS International Study (OASIS) cohort] were assessed for urinary CTX-I and -II. Results of both biochemical markers were compared with baseline scores for radiological damage (modified modified Stoke Ankylosing Spondylitis Spine Score, primarily reflecting syndesmophyte-formation and -growth), and with scores for radiological progression after 2 yrs follow-up. Markers were also associated with disease activity parameters and BMD.</p>
<p><b>Results.</b> Mean duration of complaints was 28.6 yrs. At that time, 54% of patients had signs of radiological damage, and 35% of them showed radiological progression after 2 yrs. Baseline radiological damage ( = 0.24; <I>P</I> &le; 0.05) correlated with CTX-II, but not with CTX-I. CTX-II correlated with serological markers of inflammation (ESR  = 0.29 and CRP  = 0.30; <I>P</I> &le; 0.01), but not with baseline BASDAI or BMD. There was a negative correlation between CTX-I and BMD of the trochanter ( = &ndash;0.31; <I>P</I> &le; 0.01) In multivariate analyses, CTX-II significantly and independently contributed to explaining variation in radiological damage (standardized &beta; = 0.27; <I>P</I> = 0.03) and progression (standardized &beta; = 0.27; <I>P</I> = 0.05).</p>
<p><b>Conclusion.</b> In AS, cartilage degradation plays a role in explaining radiological-damage and -progression in the spine.</p>
]]></description>
<dc:creator><![CDATA[Vosse, D., Landewe, R., Garnero, P., van der Heijde, D., van der Linden, S., Geusens, P.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Osteoarthritis and Cartilage, Spondylarthropathies]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken148</dc:identifier>
<dc:title><![CDATA[Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1222</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1219</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1223?rss=1">
<title><![CDATA[Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1223?rss=1</link>
<description><![CDATA[
<p><b>Objectives.</b> The pain intensity of patients with FM has recently been reported to be correlated with the degree of small intestinal bacterial overgrowth (SIBO). SIBO is often associated with an increased intestinal permeability (IP). Increased IP, if shown in FM, may have pathogenetic relevance because it leads to the exposure of immune cells to luminal antigens and consequent immune modulation. It is currently unknown whether IP is altered in FM. We therefore examined the IP in a group of patients with primary FM and in two control groups, healthy volunteers and patients with an unrelated chronic pain syndrome, complex regional pain syndrome (CRPS). We hypothesized that patients with FM, but not volunteers or those patients with CRPS, would have altered IP.</p>
<p><b>Methods.</b> Both gastroduodenal and small IP were assessed using an established three-sugar test, where urinary disaccharide excretion reflecting intestinal uptake was measured using HPLC.</p>
<p><b>Results.</b> Forty patients with primary FM, 57 age- and sex-matched volunteers and 17 patients with CRPS were enrolled in this study. In the FM group, 13 patients had raised gastroduodenal permeability and 15 patients had raised small intestinal permeability, but only one volunteer had increased gastroduodenal permeability (<I>P</I> &lt; 0.0001, chi-square test for the three groups). The IP values were significantly increased in the patient groups (<I>P</I> &lt; 0.0003 for all comparisons, one-way analysis of variance).</p>
<p><b>Conclusions.</b> The IPs in primary FM and, unexpectedly, CRPS are increased. This study should stimulate further research to determine the implication of altered IP in the disease pathophysiology of FM and CRPS.</p>
]]></description>
<dc:creator><![CDATA[Goebel, A., Buhner, S., Schedel, R., Lochs, H., Sprotte, G.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Fibromyalgia]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken140</dc:identifier>
<dc:title><![CDATA[Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1227</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1223</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1228?rss=1">
<title><![CDATA[Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1228?rss=1</link>
<description><![CDATA[
<p><b>Objectives.</b> The aim of this study was to determine the clinical characteristics of Behcet's disease (BD) associated with bone marrow failure (BMF), classified as conditions such as myelodysplastic syndrome (MDS) or aplastic anaemia (AA), in Korea.</p>
<p><b>Methods.</b> A retrospective analysis was made of 13 patients with BD associated with BMF (MDS 8 cases, AA 5 cases) and 66 patients with BD not associated with BMF. These patients all fulfilled the diagnostic criteria of the international BD study group.</p>
<p><b>Results.</b> BD patients with BMF showed significantly lower leucocyte count, haemoglobin level and platelet count when compared with patients without BMF (<I>P</I> &lt; 0.001). BD patients with BMF had significantly higher serum CRP level at the time of BD diagnosis compared with patients without BMF (<I>P</I> = 0.03). Intestinal lesions were more frequent in BD patients with BMF than those without BMF (61.5% <I>vs</I> 13.6%, <I>P</I> = 0.001). Cytogenetic abnormality was observed in 90.9% of BD patients with BMF. Of the cytogenetic abnormalities, trisomy 8 was most common, occurring in 70% of the patients. In four patients with refractory BD associated with BMF, successful treatment of BMF by haematopoietic stem cell transplantation resulted in clinical remission of BD.</p>
<p><b>Conclusions.</b> Our study indicates that intestinal ulceration is a characteristic finding in BD associated with BMF. It also suggests that cytogenetic aberration, especially trisomy 8, may play an important role in the pathogenesis of BD associated with BMF.</p>
]]></description>
<dc:creator><![CDATA[Ahn, J. K., Cha, H.-S., Koh, E.-M., Kim, S.-H., Kim, Y. G., Lee, C.-K., Yoo, B.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken162</dc:identifier>
<dc:title><![CDATA[Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1230</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1228</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1231?rss=1">
<title><![CDATA[Wireless capsule endoscopy in the investigation of intestinal Behcet's syndrome]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1231?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> Intestinal Beh&ccedil;et's Syndrome (BS) is a difficult diagnosis to establish. We describe the use of wireless capsule endoscopy (WCE) in the investigation of 11 patients with suspected intestinal BS.</p>
<p><b>Methods.</b> Out of 11 patients, 10 with suspected intestinal BS were found to have small intestinal ulcers on capsule endoscopy. Each case was retrospectively assessed for symptoms, signs, anaemia, other investigations, treatment and complications.</p>
<p><b>Results.</b> All 11 patients had established diagnoses of BS as defined by the International Study Group criteria. Central abdominal pain and change in bowel habit were the predominant symptoms, both occurring in seven patients. Upper gastrointestinal (GI) endoscopy and colonoscopy identified duodenitis, ileitis and colitis in three patients. Barium studies and CT were normal in all cases. WCE revealed small intestinal ulcers throughout the ileum in five patients and ulcers located either in the proximal and/or distal ileum in five other patients. One patient had significant symptoms, signs and ulcers leading to a change in treatment to infliximab, and this resulted in resolution of symptoms and ulcers. Ten age- and sex-matched controls investigated for unexplained GI symptoms had no intestinal lesions on capsule endoscopy.</p>
<p><b>Conclusion.</b> WCE is useful in the investigation of GI symptoms in BS. It is particularly helpful in those patients in whom conventional investigations have been normal or fail to account for symptoms and signs. This technique may guide treatment and provide a better understanding of intestinal pathology in BS.</p>
]]></description>
<dc:creator><![CDATA[Hamdulay, S. S., Cheent, K., Ghosh, C., Stocks, J., Ghosh, S., Haskard, D. O.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken216</dc:identifier>
<dc:title><![CDATA[Wireless capsule endoscopy in the investigation of intestinal Behcet's syndrome]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1234</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1231</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1235?rss=1">
<title><![CDATA[Glucose regulation and chronic pain at multiple sites]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1235?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> To analyse how glucose regulation status is associated with chronic regional pain and chronic widespread pain (CWP) in the adult population.</p>
<p><b>Methods.</b> A structured interview and health examination study with 480 participants aged 30&ndash;65 yrs was carried out in Lapinlahti municipality in eastern Finland. The number of painful sites in the right or left upper and lower extremities, shoulders and hips, and in neck and back was summated. Those subjects with chronic pain in at least four sites were defined as having CWP. Diabetes and glucose tolerance status diagnosis were based on self-reported diagnoses, reimbursed medication and laboratory tests. Subjects with impaired fasting plasma glucose and/or elevated 2-h glucose level were combined into a group of impaired glucose regulation (IGR).</p>
<p><b>Results.</b> Of the total sample, 55 subjects (11%) had diabetes. The prevalence of CWP was 13% (<I>n</I> = 62) in all subjects. The corresponding percentages for subjects with normal glucose regulation, IGR and diabetes were 9, 18 and 28%. In the multivariate analysis, diabetes was associated with CWP (odds ratio = 2.99; 95% CI 1.19, 7.53; <I>P</I> = 0.020).</p>
<p><b>Conclusions.</b> These results point to a significant association between diabetes and CWP in the adult population.</p>
]]></description>
<dc:creator><![CDATA[Mantyselka, P., Miettola, J., Niskanen, L., Kumpusalo, E.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Psychology: Measurement and Management of Pain]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken220</dc:identifier>
<dc:title><![CDATA[Glucose regulation and chronic pain at multiple sites]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1238</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1235</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1239?rss=1">
<title><![CDATA[Micro magnetic resonance angiography of the finger in systemic sclerosis]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1239?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> To characterize vascular lesions in SSc disease with high-resolution magnetic resonance angiography (Micro-MRA) of the finger.</p>
<p><b>Methods.</b> Eight SSc subjects and eight age- and sex-matched healthy controls were recruited for this study. Among the SSc subjects, the mean &plusmn; <scp>s.d</scp>. age was 54.5 &plusmn; 4.9 yrs, and the mean &plusmn; <scp>s.d</scp>. duration of disease was 8.3 &plusmn; 8.4 yrs. The numbers of SSc subjects that had telangiectasia, calcinosis and impaired finger flexion were 3, 2 and 3, respectively. The 2D time-of-flight micro-MRA was performed on a 3T clinical MRI scanner using a custom-designed finger coil with an in-plane resolution of 0.16 <FONT FACE="arial,helvetica">x</FONT> 0.21 mm<sup>2</sup> and slice thickness of 1.2 mm. The data for the proper palmar digital artery lumen area, the number of visible dorsal digital veins and a semi-quantitative vascular score, which evaluates the overall integrity of digital vessels, were independently evaluated by two experienced reviewers who were blinded to the status of the subject.</p>
<p><b>Results.</b> Micro-MRA detected significant differences in the digital vasculature between SSc subjects and healthy volunteers. The SSc subjects had a significantly decreased digital artery lumen area (0.13 &plusmn; 0.06 <I>vs</I> 0.53 &plusmn; 0.26 mm<sup>2</sup>, <I>P</I> &lt; 0.001), a reduced number of digital veins (0.63 &plusmn; 1.06 <I>vs</I> 3.13 &plusmn; 0.99, <I>P</I> = 0.001) and a lowered overall vascular score (1.75 &plusmn; 1.04 <I>vs</I> 3.5 &plusmn; 0.53, <I>P</I> = 0.001). The study also found that both the digital artery lumen area (Pearson's; <I>r</I> = &ndash;0.72, <I>P</I> = 0.044) and vascular scores (Spearman's; <I></I> = &ndash;0.75, <I>P</I> = 0.047) of the SSc subjects were inversely correlated with the duration of the disease.</p>
<p><b>Conclusions.</b> Micro-MRA can be used to identify and quantitatively characterize the vascular disease in SSc fingers. The parameters derived from micro-MRA could potentially be used as prospective biomarkers for clinical evaluation.</p>
]]></description>
<dc:creator><![CDATA[Wang, J., Yarnykh, V. L., Molitor, J. A., Nash, R. A., Chu, B., Wilson, G. J., Fleming, J., Schwartz, S. M., Yuan, C.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Systemic Sclerosis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken215</dc:identifier>
<dc:title><![CDATA[Micro magnetic resonance angiography of the finger in systemic sclerosis]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1243</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1239</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1244?rss=1">
<title><![CDATA[Ultrasonography of salivary glands in primary Sjogren's syndrome: a comparison with contrast sialography and scintigraphy]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1244?rss=1</link>
<description><![CDATA[
<p><b>Objective.</b> To compare ultrasonography (US) of salivary glands with contrast sialography and scintigraphy, in order to evaluate the diagnostic value of this method in primary SS (pSS).</p>
<p><b>Methods.</b> The diagnostic value of parotid gland US was studied in 77 patients with pSS (male/female ratio 3/74; mean age 54 yrs) and in 79 with sicca symptoms but without SS. The two groups were matched for sex and age. Imaging findings of US were graded using an ultrasonographic score ranging from 0 to 16, which was obtained by the sum of the scores for each parotid and submandibular gland. The sialographic and scintigraphic patterns were classified in four different stages. The area under receiver operating characteristic curve (AUC-ROC) was employed to evaluate the screening method's performance.</p>
<p><b>Results.</b> Of the 77 patients with pSS, 66 had abnormal US findings. Mean US score in pSS patients was 9.0 (range from 3 to 16). Subjects without confirmed pSS had the mean US score 3.9 (range from 0 to 9) (<I>P</I> &lt; 0.0001). Results of sialography showed that 59 pSS patients had abnormal findings at Stage 1 (<I>n</I> = 4), Stage 2 (<I>n</I> = 8), Stage 3 (<I>n</I> = 33) or Stage 4 (<I>n</I> = 14), and 58 patients had abnormal scintigraphic findings at Stage 1 (<I>n</I> = 11), Stage 2 (<I>n</I> = 18), Stage 3 (<I>n</I> = 25) or Stage 4 (<I>n</I> = 4). Through ROC curves US arose as the best performer (AUC = 0.863 &plusmn; 0.030), followed by sialography (AUC = 0.804 &plusmn; 0.035) and by salivary gland scintigraphy (AUC = 0.783 &plusmn; 0.037). The difference between AUC-ROC curve of salivary gland US and scintigraphy was significant (<I>P</I> = 0.034). Setting the cut-off score &gt;6 US resulted in the best ratio of sensitivity (75.3%) to specificity (83.5%), with a likelihood ratio of 4.58. If a threshold &gt;8.0 was applied the test gained specificity, at the cost of a serious loss of sensitivity (sensitivity 54.5%, specificity 97.5%, likelihood ratio 21.5).</p>
<p><b>Conclusions.</b> Salivary gland US is a useful method in visualizing glandular structural changes in patients suspected of having pSS and it may represent a good option as a first-line imaging tool in the diagnostics of the disease.</p>
]]></description>
<dc:creator><![CDATA[Salaffi, F., Carotti, M., Iagnocco, A., Luccioli, F., Ramonda, R., Sabatini, E., De Nicola, M., Maggi, M., Priori, R., Valesini, G., Gerli, R., Punzi, L., Giuseppetti, G. M., Salvolini, U., Grassi, W.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Sjogren's Syndrome]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken222</dc:identifier>
<dc:title><![CDATA[Ultrasonography of salivary glands in primary Sjogren's syndrome: a comparison with contrast sialography and scintigraphy]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1249</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1244</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1250?rss=1">
<title><![CDATA[Working with folk arts may produce benefits to rheumatic patients: the case of Grandma Moses]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1250?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Azevedo, V. F.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken227</dc:identifier>
<dc:title><![CDATA[Working with folk arts may produce benefits to rheumatic patients: the case of Grandma Moses]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1250</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1250</prism:startingPage>
<prism:section>HEBERDEN HISTORICAL SERIES</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1251?rss=1">
<title><![CDATA[Arthropathy in paediatric inflammatory bowel disease: a cross-sectional observational study]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1251?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[McErlane, F., Gillon, C., Irvine, T., Davidson, J. E., Casson, D., Dalzell, A. M., Beresford, M. W.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:identifier>info:doi/10.1093/rheumatology/ken217</dc:identifier>
<dc:title><![CDATA[Arthropathy in paediatric inflammatory bowel disease: a cross-sectional observational study]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1252</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1251</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1252?rss=1">
<title><![CDATA[An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1252?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Teir, J., Koduri, G., Meadows, A., Griffin, J., Kelsey, C., Kola, A., Persey, M., Sinclair, H., Yuksel, F., Moshtaghi, P., Ramabhadram, B., Poole, K., Pradeep, J., Lane, S., Pountain, G., Scott, D. G. I., Sheehan, N. J., Stodell, M., Young, A., Hall, F. C.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis, Systemic Lupus Erythematosus and Autoimmunity]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken232</dc:identifier>
<dc:title><![CDATA[An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1254</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1252</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1254?rss=1">
<title><![CDATA[Acute psychosis in three patients receiving anti-tumour necrosis factor-{alpha} therapy]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1254?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[McGregor, L., Saunders, S. A., Hunter, J. A., Murphy, E.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Spondylarthropathies, Pharmacology, Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken212</dc:identifier>
<dc:title><![CDATA[Acute psychosis in three patients receiving anti-tumour necrosis factor-{alpha} therapy]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1255</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1254</prism:startingPage>
<prism:section>CASE REPORTS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1255?rss=1">
<title><![CDATA[A synovial pathergy reaction leading to a pseudo-septic arthritis and a diagnosis of Behcet's disease]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1255?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Humby, F., Gullick, N., Kelly, S., Pitzalis, C., Oakley, S. P.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken194</dc:identifier>
<dc:title><![CDATA[A synovial pathergy reaction leading to a pseudo-septic arthritis and a diagnosis of Behcet's disease]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1256</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1255</prism:startingPage>
<prism:section>CASE REPORTS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1256?rss=1">
<title><![CDATA[Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1256?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Teichmann, L. L., Woenckhaus, M., Vogel, C., Salzberger, B., Scholmerich, J., Fleck, M.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken234</dc:identifier>
<dc:title><![CDATA[Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1257</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1256</prism:startingPage>
<prism:section>CASE REPORTS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1257?rss=1">
<title><![CDATA[Inflammatory aortitis controlled by the Chinese herbal remedy Donglingcao Pian]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1257?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[De Silva, C., Stevens, R., Jordan, K. M.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken209</dc:identifier>
<dc:title><![CDATA[Inflammatory aortitis controlled by the Chinese herbal remedy Donglingcao Pian]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1259</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1257</prism:startingPage>
<prism:section>CASE REPORTS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1259?rss=1">
<title><![CDATA[Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1259?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Bateman, J., Penfold, R., Rigby, S. P.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken189</dc:identifier>
<dc:title><![CDATA[Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1259</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1259</prism:startingPage>
<prism:section>MATTERS ARISING</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1259-a?rss=1">
<title><![CDATA[Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study: reply]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1259-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Karie, S., Launay-Vacher, V., Gandjbakhch, F., Janus, N., Rozenberg, S., Bourgeois, P., Deray, G.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken239</dc:identifier>
<dc:title><![CDATA[Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study: reply]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1260</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1259</prism:startingPage>
<prism:section>MATTERS ARISING</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1260?rss=1">
<title><![CDATA[Comment on: Sparing of the thumb in Raynaud's phenomenon: reply]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1260?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Chikura, B., Moore, T., Manning, J., Vail, A., Herrick, A. L.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Systemic Sclerosis, Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken221</dc:identifier>
<dc:title><![CDATA[Comment on: Sparing of the thumb in Raynaud's phenomenon: reply]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1260</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1260</prism:startingPage>
<prism:section>MATTERS ARISING</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1260-a?rss=1">
<title><![CDATA[Comment on: Sparing of the thumb in Raynaud's phenomenon]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1260-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Binymin, K. A.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Systemic Sclerosis, Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken228</dc:identifier>
<dc:title><![CDATA[Comment on: Sparing of the thumb in Raynaud's phenomenon]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1260</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1260</prism:startingPage>
<prism:section>MATTERS ARISING</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261?rss=1">
<title><![CDATA[CONTEMPORARY TARGETED THERAPIES IN RHEUMATOLOGY, Edited by J. S. Smolen and P. E. Lipsky.]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Muller-Ladner, U.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Spondylarthropathies, Experimental Arthritis, Rheumatoid Arthritis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken211</dc:identifier>
<dc:title><![CDATA[CONTEMPORARY TARGETED THERAPIES IN RHEUMATOLOGY, Edited by J. S. Smolen and P. E. Lipsky.]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1261</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1261</prism:startingPage>
<prism:section>BOOK REVIEWS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261-a?rss=1">
<title><![CDATA[VASCULITIS, 2ND Edn. Edited by G. V. Balls and S. L. Bridges, Jr.]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[De Keyser, F.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Vasculitis]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken213</dc:identifier>
<dc:title><![CDATA[VASCULITIS, 2ND Edn. Edited by G. V. Balls and S. L. Bridges, Jr.]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1261</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1261</prism:startingPage>
<prism:section>BOOK REVIEWS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261-b?rss=1">
<title><![CDATA[LUPUS, 2ND Edn. Edited by D. Isenberg and S. Manzi.]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1261-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Hoffman, I.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Systemic Lupus Erythematosus and Autoimmunity]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken218</dc:identifier>
<dc:title><![CDATA[LUPUS, 2ND Edn. Edited by D. Isenberg and S. Manzi.]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1262</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1261</prism:startingPage>
<prism:section>BOOK REVIEWS</prism:section>
</item>

<item rdf:about="http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1262?rss=1">
<title><![CDATA[CURRENT RHEUMATOLOGY DIAGNOSIS & TREATMENT, 2ND Edn, Edited by J. Imboden, D. Hellmann and J. Stone.]]></title>
<link>http://rheumatology.oxfordjournals.org/cgi/content/short/47/8/1262?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Khurshid, M. A.]]></dc:creator>
<dc:date>2008-07-16</dc:date>
<dc:subject><![CDATA[Osteoarthritis and Cartilage, Systemic Sclerosis, Myositis and Muscle Disease, Vasculitis, Spondylarthropathies, Fibromyalgia, Diagnostics and Imaging Procedures, Osteoporosis and Metabolic Bone Disease, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Autoimmunity]]></dc:subject>
<dc:identifier>info:doi/10.1093/rheumatology/ken214</dc:identifier>
<dc:title><![CDATA[CURRENT RHEUMATOLOGY DIAGNOSIS & TREATMENT, 2ND Edn, Edited by J. Imboden, D. Hellmann and J. Stone.]]></dc:title>
<dc:publisher>British Society for Rheumatology</dc:publisher>
<prism:number>8</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>1262</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>1262</prism:startingPage>
<prism:section>BOOK REVIEWS</prism:section>
</item>

</rdf:RDF>